NDAORALTABLET
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVETEN HCT is a fixed-dose combination oral tablet containing eprosartan mesylate (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) approved in 2001 for hypertension management. It combines two complementary antihypertensive mechanisms to reduce blood pressure in patients requiring dual-agent therapy. The ARB component blocks angiotensin II receptors while the diuretic promotes sodium and water excretion.
LOE Approaching
As LOE approaches, commercial teams are likely transitioning to defend market share against generic erosion rather than drive growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TEVETEN HCT in its LOE phase offers limited growth trajectory but valuable experience in defensive marketing, generic preparation, and lifecycle management. Roles emphasize maintaining market position, managing payer relationships, and supporting transition planning rather than launch or expansion.
Brand ManagerMedical Science Liaison
Worked on TEVETEN HCT at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.